Silo Pharma, Inc. (SILO) SEC filings

SILONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30

$1.84−0.07 (-3.66%)

Close on Nov 13, 2026Market cap $2.92MP/E –Yield –

SEC filings

40 of Silo Pharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 14, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 2, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 19, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 17, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 9, 2026	Jul 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Aug 14, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 1, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	Mar 30, 2026	Apr 2, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 27, 2026	SEC EDGAR
Current report	8-K	Feb 20, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Dec 24, 2025	Dec 29, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Oct 24, 2025	Oct 24, 2025	SEC EDGAR
Current report	8-K	Sep 29, 2025	Oct 1, 2025	SEC EDGAR
Proxy statement	DEF 14A	Oct 24, 2025	Sep 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 4, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Jul 29, 2025	Jul 29, 2025	SEC EDGAR
Current report	8-K	Jul 8, 2025	Jul 10, 2025	SEC EDGAR
Current report	8-K	Jun 27, 2025	Jul 3, 2025	SEC EDGAR
Current report	8-K	May 15, 2025	May 16, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 10, 2025	Mar 10, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 7, 2025	SEC EDGAR
Current report	8-K	Jan 2, 2025	Jan 2, 2025	SEC EDGAR
Current report	8-K	Dec 20, 2024	Dec 20, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 8, 2024	Nov 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	Nov 12, 2024	Sep 18, 2024	SEC EDGAR
Current report	8-K	Sep 10, 2024	Sep 10, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Jul 18, 2024	Jul 22, 2024	SEC EDGAR
Current report	8-K	Jul 1, 2024	Jul 8, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Silo Pharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Jun 3, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SILO.

Compare: SILO vs IXHL · SILO vs ASBP · SILO vs AVTX · SILO vs ADXN · SILO vs KZIA

Company	Revenue	Growth
ASBP	$97.66K	–
SILO	$36.05K	-50.0%
IXHL	–	–
AVTX	–	–
ADXN	–	–
KZIA	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 3
Held by institutions: 9.0%
Auditor: Salberg& Company, P.A.
SEC CIK: 1514183

Advertisement
300 × 250

See a number that looks wrong?